Inactivation of the p53 pathway is a universal event in human cancers and promotes tumorigenesis and resistance to chemotherapy. Inactivating p53 mutations are uncommon in non-complex karyotype leukemias, thus the p53-pathway must be inactivated by other mechanisms. The Apoptosis Stimulating Protein of p53-2 (ASPP2) is a damage-inducible p53-binding protein that enhances apoptosis at least in part through a p53-mediated pathway. We have previously shown, that ASPP2 is an independent haploinsufficient tumor suppressor in vivo. Now, we reveal that ASPP2 expression is significantly attenuated in acute myeloid and lymphoid leukemia – especially in patients with an unfavorable prognostic risk profile and patients who fail induction chemotherapy. In line, knock down of ASPP2 in expressing leukemia cell lines and native leukemic blasts attenuates damage-induced apoptosis. Furthermore, cultured blasts derived from high-risk leukemias fail to induce ASPP2 expression upon anthracycline treatment. The mechanisms of ASPP2 dysregulation are unknown. We provide evidence that attenuation of ASPP2 is caused by hypermethylation of the promoter and 5′UTR regions in native leukemia blasts. Together, our results suggest that ASPP2 contributes to the biology of leukemia and expression should be further explored as a potential prognostic and/or predictive biomarker to monitor therapy responses in acute leukemia.
References
[1]
Vousden KH, Prives C (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413–431.
[2]
Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, et al. (2012) Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A 109: 9551–9556.
[3]
Kaneko H, Misawa S, Horiike S, Nakai H, Kashima K (1995) TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85: 2189–2193.
[4]
Misawa S, Horiike S (1996) TP53 mutations in myelodysplastic syndrome. Leuk Lymphoma 23: 417–422.
[5]
Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, et al. (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12: 887–892.
[6]
Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, et al. (1979) TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 29: 1971–1979.
[7]
Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, et al. (1989) Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 74: 2318–2324.
[8]
Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, et al. (2010) TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28: 4473–4479.
[9]
Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, et al. (2006) Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A 103: 7444–7449.
[10]
Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, et al. (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 119: 2114–2121.
[11]
Joannides M, Grimwade D (2010) Molecular biology of therapy-related leukaemias. Clin Transl Oncol 12: 8–14.
[12]
Haferlach T (2008) Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program: 400–411.
[13]
Seifert H, Mohr B, Thiede C, Oelschlagel U, Schakel U, et al. (2009) The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia 23: 656–663.
[14]
Samuels-Lev Y, O'Connor D, Bergamaschi D, Trigiante G, Campargue I, et al. (2001) ASPP Proteins Specifically Stimulate the Apoptotic Function of p53. Molecular Cell 8: 781–794.
[15]
Kampa KM, Acoba JD, Chen D, Gay J, Lee H, et al. (2009) Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci U S A 106: 4390–4395.
[16]
Vives V, Su J, Zhong S, Ratnayaka I, Slee E, et al. (2006) ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev 20: 1262–1267.
[17]
Lossos IS, Natkunam Y, Levy R, Lopez CD (2002) Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma 43: 2309–2317.
[18]
Lopez CD, Ao Y, Rohde L, Perez T, O'Connor D, et al. (2000) Proapoptotic p53-Interacting Protein 53BP2 Is Induced by UV Irradiation but Suppressed by p53. Molecular and Cellular Biology 20: 8018–8025.
[19]
Zhu Z, Ramos J, Kampa K, Adimoolam S, Sirisawad M, et al. (2005) Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function. J Biol Chem 280: 34473–34480.
[20]
Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC (2009) The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 8: 2621–2630.
[21]
Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, et al. (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66: 473–481.
[22]
Rollig C, Bornhauser M, Thiede C, Taube F, Kramer M, et al. (2011) Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 29: 2758–2765.
[23]
Lopez CD, Ao Y, Rohde LH, Perez TD, O'Connor DJ, et al. (2000) Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53. Mol Cell Biol 20: 8018–8025.
[24]
Robinson RA, Lu X, Jones EY, Siebold C (2008) Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure 16: 259–268.
[25]
Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, et al. (2004) ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 24: 1341–1350.
[26]
Kampa KM, Bonin M, Lopez CD (2009) New insights into the expanding complexity of the tumor suppressor ASPP2. Cell Cycle 8: 2871–2876.
[27]
Wang Z, Liu Y, Takahashi M, Van Hook K, Kampa-Schittenhelm KM, et al. (2013) N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence. Proc Natl Acad Sci U S A 110: 312–317.
[28]
Wang XD, Lapi E, Sullivan A, Ratnayaka I, Goldin R, et al. (2010) SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence. Cell Death Differ 18: 304–314.
[29]
Liu CY, Lv X, Li T, Xu Y, Zhou X, et al. (2011) PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ. J Biol Chem 286: 5558–5566.
[30]
Cong W, Hirose T, Harita Y, Yamashita A, Mizuno K, et al. (2010) ASPP2 regulates epithelial cell polarity through the PAR complex. Curr Biol 20: 1408–1414.
[31]
Sottocornola R, Royer C, Vives V, Tordella L, Zhong S, et al. (2010) ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell 19: 126–137.
[32]
Wang Y, Wang XD, Lapi E, Sullivan A, Jia W, et al. (2012) Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci U S A 109: 13325–13330.
[33]
Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T (2008) Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 7: 699–708.
[34]
Laumann R, Jucker M, Tesch H (1992) Point mutations in the conserved regions of the p53 tumour suppressor gene do not account for the transforming process in the Jurkat acute lymphoblastic leukemia T-cells. Leukemia 6: 227–228.
[35]
Chen D, Padiernos E, Ding F, Lossos IS, Lopez CD (2005) Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene. Cell Death Differ 12: 358–368.
[36]
Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, et al. (2011) DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One 6: e14524.
[37]
Zhao J, Wu G, Bu F, Lu B, Liang A, et al. (2010) Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 51: 142–153.
